FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60 | -54.9% | 28,193 | +1.0% | 0.00% | – |
| Q2 2023 | $133 | -16.9% | 27,907 | -0.3% | 0.00% | – |
| Q1 2023 | $160 | -77.7% | 27,983 | -60.5% | 0.00% | -100.0% |
| Q4 2022 | $716 | -100.0% | 70,928 | -5.9% | 0.00% | -50.0% |
| Q3 2022 | $1,690,000 | -1.1% | 75,394 | +9.4% | 0.00% | 0.0% |
| Q2 2022 | $1,708,000 | -35.4% | 68,908 | +1.0% | 0.00% | -33.3% |
| Q1 2022 | $2,646,000 | -27.4% | 68,244 | +9.5% | 0.00% | -25.0% |
| Q4 2021 | $3,647,000 | +6.2% | 62,334 | +7.6% | 0.00% | 0.0% |
| Q3 2021 | $3,435,000 | -51.0% | 57,948 | -28.3% | 0.00% | -42.9% |
| Q2 2021 | $7,010,000 | +15.8% | 80,767 | +10.0% | 0.01% | 0.0% |
| Q1 2021 | $6,056,000 | +3.1% | 73,445 | +13.7% | 0.01% | 0.0% |
| Q4 2020 | $5,874,000 | +140.1% | 64,600 | +5.6% | 0.01% | +133.3% |
| Q3 2020 | $2,446,000 | +24.0% | 61,200 | +6.4% | 0.00% | 0.0% |
| Q2 2020 | $1,973,000 | +62.7% | 57,500 | +5.3% | 0.00% | +50.0% |
| Q1 2020 | $1,213,000 | +13.5% | 54,600 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $1,069,000 | +28.5% | 54,600 | +1.9% | 0.00% | 0.0% |
| Q3 2019 | $832,000 | -23.5% | 53,600 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,088,000 | -32.9% | 53,600 | -41.9% | 0.00% | -50.0% |
| Q1 2019 | $1,622,000 | +141.4% | 92,290 | +76.1% | 0.00% | +100.0% |
| Q4 2018 | $672,000 | -21.3% | 52,400 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $854,000 | +43.8% | 52,400 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $594,000 | +50.4% | 52,400 | +29.4% | 0.00% | – |
| Q1 2018 | $395,000 | +59.9% | 40,500 | 0.0% | 0.00% | – |
| Q4 2017 | $247,000 | +54.4% | 40,500 | 0.0% | 0.00% | – |
| Q3 2017 | $160,000 | +22.1% | 40,500 | 0.0% | 0.00% | – |
| Q2 2017 | $131,000 | – | 40,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |